London-based startup BenevolentAI, which uses artificial intelligence (AI) to develop new medicines has raised $115 million at a valuation of $2 billion. New and existing investor participated in the funding round of BenevolentAI which has raised over $200 million since it was founded in 2013. BenevolentAI claims its technology outperforms human scientists in understanding the cause of diseases.